Jonathan Gardner is a Senior Reporter for BioPharma Dive, with his work also appearing in Healthcare Dive and Yahoo Finance. With a focus on the pharmaceutical industry, Jonathan covers a wide range of topics including drug trials, FDA approvals, pricing, and the latest developments in the biopharmaceutical sector.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
This information evolves through artificial intelligence and human feedback. Improve this profile .
The expansion of a newly acquired facility in Wisconsin will help Lilly ramp up production of injectable drugs like its fast-selling Zepbound.
By: Jonathan Gardner, Ned Pagliarulo, Ben Fidler
J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH mid-stage findings for important new medicines.
By: Jonathan Gardner
While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace fulvestrant.
News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.
The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair of mid-stage trials.
By: Jonathan Gardner
Novo shares lost nearly a quarter of their value after an experimental combination treatment called cagrisema fell short of the bar set by executives.
By: Jonathan Gardner
In This Article NVO LLY Show Quick Summary
With Paul Aktins as chair, the US regulator can be expected to roll back policies supporting ESG goals, according to lawyers at Labaton Keller Sucharow LLP
August 1, 2006 | Rheumatology News Author and Disclosure Information
August 1, 2006 | Rheumatology News Author and Disclosure Information
(833) 317-6278 
